mt logoMyToken
ETH Gas
简体中文

Tang Capital Reports Zero Capricor Stake After Stock Plunges 13%

Capricor Therapeutics (NASDAQ: CAPR) shares fell about 13% to $8.30 on Monday, extending their losing streak to three sessions. The decline preceded an after-hours SEC filing in which Tang Capital Management and its affiliates reported zero beneficial ownership of the company’s shares as of September 30.

The disclosure marked a change from an earlier filing in which Tang Capital and its related reporting parties disclosed beneficial ownership of 4,099,900 CAPR shares, or approximately 7.1% of the company’s outstanding common stock, as of June 30.

A separate Form 13F filed Monday also showed no CAPR shares among Tang Capital’s reported holdings as of September 30. Neither filing provides transaction dates or sale prices explaining the change in its reported position.

Tang Capital was not the only previously disclosed major shareholder to report zero ownership. A separate SEC filing submitted after Friday’s market close showed that Montanova Capital, Averill Master Fund and Aaron Cowen also reported zero beneficial ownership of Capricor shares as of September 30. Montanova, formerly known as Suvretta Capital Management, had reported beneficial ownership of 3,417,891 CAPR shares, representing 6.6% of the company’s outstanding stock, in a February filing.

Deramiocel Application Remains Under FDA Review

The disclosures come ahead of the Food and Drug Administration’s November 22 target action date for Deramiocel, Capricor’s investigational cell therapy for Duchenne muscular dystrophy (DMD), a genetic disorder in which muscles progressively weaken.

The FDA had previously declined to approve Deramiocel in July 2025 and requested additional clinical data. Capricor subsequently resubmitted its application with evidence from the Phase 3 HOPE-3 trial.

At a July 2026 FDA advisory committee meeting, members voted 9-3 against finding sufficient evidence to support Deramiocel’s effectiveness in treating cardiomyopathy in DMD patients. The vote did not address the endpoint measuring upper-limb function in the Phase 3 HOPE-3 trial, and the committee’s recommendation is not binding on the FDA.

Following the meeting, Capricor amended its biologics license application (BLA) in August to include 24-month open-label extension data from HOPE-3 , additional analyses and a refined proposed indication focused on upper-limb impairment in patients older than nine years. The FDA classified the submission as a major amendment, extending the original August 22 target action date by three months.

In its latest quarterly filing , Capricor warned that the agency could issue a Complete Response Letter declining to approve the amended application in its current form or delay approval if regulatory requirements are not satisfied or additional testing or information is needed.

CAPR Stock and CAPRon Price Update

CAPR shares closed Monday about 26% below their November 11 closing price of $11.22. However, the stock rebounded 5.19% to $8.73 in Tuesday’s premarket trading at the time of reporting.

Meanwhile, Capricor Therapeutics Tokenized Stock (CAPRon) was trading at $8.29, down 6.32% over the past 24 hours, according to CoinMarketCap. The tokenized instrument trades separately from Nasdaq-listed CAPR shares, and its 24-hour price change does not represent the stock’s regular-session performance.

免责声明:本文版权归原作者所有,不代表MyToken(www.mytokencap.com)观点和立场;如有关于内容、版权等问题,请与我们联系。
更多精彩内容请查阅
X(https://x.com/MyTokencap)
或加入社区了解更多MyToken-官方华文电报群
(https://t.me/mytoken_cn)